var data={"title":"Caspofungin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Caspofungin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5831?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">see &quot;Caspofungin: Drug information&quot;</a> and <a href=\"topic.htm?path=caspofungin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Caspofungin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146788\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cancidas</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146789\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cancidas</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045813\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antifungal Agent, Echinocandin</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antifungal Agent, Systemic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442199\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Caspofungin treatment duration should be based on patient status and clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis, invasive infections: </b>Limited data available: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>BSA-directed dosing: </i>25 mg/m<sup>2</sup>/dose once daily (Bradley 2017; IDSA [Pappas 2016]); dosing based on a pharmacokinetic study of 18 neonates (PNA: &lt;12 weeks; GA &ge;28 weeks (all except one patient); weight at enrollment: &ge;500 g; most [n=16] were &ge;1 kg); results showed similar serum concentrations to standard adult doses. Reported trough concentrations were slightly elevated and not correlated with increased adverse events (S&aacute;ez-Llorens 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Weight-directed dosing:</i> 2 mg/<b>kg</b>/dose once daily; treatment should continue for at least 2 weeks after the first negative blood culture and signs and symptoms have resolved (IDSA [Pappas 2016]); dosing based on a prospective, randomized, double-blind study and a case series; the prospective trial enrolled 32 patients with invasive candidiasis and randomized them to receive caspofungin (n=15; GA: 27.9 &plusmn; 1.3 weeks; PNA at onset of candida infection: 21.1 &plusmn; 3.1 days) or amphotericin B as initial treatment; results showed that the caspofungin group had a significantly higher response rate compared to the amphotericin B group (86.7% favorable response vs 41.7%); the caspofungin group also experienced significantly fewer adverse effects (Mohamed 2012); the case series included seven premature neonates (GA: 23 to 24 weeks, PNA at treatment, range: 13 to 53 days) with <i>Candida </i>infections refractory to amphotericin B; results showed this regimen to be effective and well tolerated for the treatment of <i>C. parapsilosis</i> and <i>C. albicans</i> (Jeon 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045806\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">see &quot;Caspofungin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Caspofungin treatment duration should be based on patient status and clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Aspergillosis, invasive; treatment: Note:</b> Guidelines recommend caspofungin for salvage therapy or where other antifungals are contraindicated; not recommended for routine use for primary treatment (IDSA [Patterson 2016]). Infants &ge;3 months, Children, and Adolescents &lt;18 years: IV: Initial 70 mg/m<sup>2</sup>/dose on day 1, then 50 mg/m<sup>2</sup>/dose once daily; may increase to 70 mg/m<sup>2</sup>/dose once daily if clinical response inadequate; maximum dose: 70 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Fungal infections, empiric therapy in neutropenic patients</b>: Infants &ge;3 months, Children, and Adolescents &lt;18 years: IV: Initial dose: 70 mg/m<sup>2</sup>/dose on day 1, then 50 mg/m<sup>2</sup>/dose once daily; may increase to 70 mg/m<sup>2</sup>/dose once daily if clinical response inadequate; maximum dose: 70 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>\n        <b>Candida </b></i>\n      <b>infections, treatment</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Non-HIV-exposed/-positive:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &lt;3 months: Limited data available: IV: 25 mg/m<sup>2</sup>/dose once daily; dosing based on a pharmacokinetic study of 18 infants (PNA &le;12 weeks) that showed similar serum concentrations to standard adult doses (50 mg/day). Reported trough concentrations were slightly elevated and not correlated with increased adverse events (S&aacute;ez-Llorens 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;3 months, Children, and Adolescents &lt;18 years: IV: Initial 70 mg/m<sup>2</sup>/dose on day 1, then 50 mg/m<sup>2</sup>/dose once daily; may increase to 70 mg/m<sup>2</sup>/dose once daily if clinical response inadequate; maximum dose: 70 mg/dose. For esophageal disease, treat for 7 to 14 days after symptom resolution. For candidemia, treat until 2 weeks after the last positive blood culture.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV-exposed/-positive: </i>Treatment duration varies based on site of infection: For esophageal disease, treat for a minimum of 3 weeks and for at least 2 weeks after resolution of symptoms and for candidemia, treat until 2 weeks after the last positive blood culture (HHS [OI pediatric 2016]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &lt;3 months: Limited data available: IV: 25 mg/m<sup>2</sup>/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants &ge;3 months, Children, and Adolescents &le;17 years: IV: Initial 70 mg/m<sup>2</sup>/dose on day 1, then 50 mg/m<sup>2</sup>/dose once daily; maximum dose: 70 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;18 years: IV: Initial 70 mg on day 1, then 50 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Aspergillosis, invasive (salvage therapy):</b> IV: Initial dose: 70 mg on day 1; followed by 50 mg once daily. Duration of therapy should be a minimum of 6 to 12 weeks and depends on site of infection, extent of disease, and level/duration of immunosuppression (IDSA [Patterson 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Candidemia</i> and other <i>Candida</i> infections:</b> IV: Initial dose: 70 mg on day 1, followed by 50 mg once daily; generally continue for at least 14 days after the last positive culture or longer if neutropenia warrants. Doses greater than the standard adult dosing regimen (ie, 150 mg once daily) have not demonstrated increased benefit or toxicity in patients with invasive candidiasis (Betts 2009). <b>Note:</b> IDSA Candidiasis guidelines recommend transition to fluconazole (usually after 5 to 7 days in non-neutropenic patients) in clinically stable patients with fluconazole-susceptible isolates and negative repeat cultures (IDSA [Pappas 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis, chronic disseminated (hepatosplenic):</b> IV: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg daily for several weeks, followed by oral fluconazole therapy (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis, empiric therapy (non-neutropenic ICU patients): </b>IV: Initial dose: 70 mg on day 1; subsequent dosing: 50 mg once daily. Consider discontinuing after 4 to 5 days in patients with no clinical response; continue treatment for 2 weeks in patients who improve on antifungal therapy (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis, esophageal</b>: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling: 50 mg once daily with no loading dose; continue for 7 to 14 days after symptom resolution.<b> Note:</b> The majority of patients studied for this indication also had oropharyngeal involvement.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate recommendation: Initial dose: 70 mg on day 1; followed by 50 mg once daily; may transition to oral fluconazole therapy once oral intake tolerable. In patients with fluconazole-refractory disease, continue caspofungin for 14 to 21 days (IDSA [Pappas 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis, esophageal, in HIV-infected patients:</b> IV: 50 mg once daily; continue for 14 to 21 days (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis, intravascular infections (native or prosthetic valve endocarditis, infection of implantable cardiac devices, suppurative thrombophlebitis):</b> IV: 150 mg daily. For native or prosthetic valve endocarditis, therapy should continue for at least 6 weeks after valve replacement surgery (longer durations in patients with abscesses or other complications); for patients with implantable cardiac devices, therapy should continue for 4 to 6 weeks after surgery (4 weeks for infections limited to generator pockets and at least 6 weeks for infections involving the wires); for suppurative thrombophlebitis, continue for at least 2 weeks after candidemia has cleared. <b>Note:</b> Step-down to fluconazole therapy is recommended in clinically stable patients with fluconazole-susceptible isolates and negative repeat cultures (IDSA [Pappas 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis, osteoarticular infections (osteomyelitis or septic arthritis) (alternative therapy):</b> IV: 50 to 70 mg daily for at least 14 days, followed by fluconazole (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis, prophylaxis against invasive candidiasis (high-risk ICU patients in units with a high rate of invasive candidiasis) (alternative therapy):</b> IV: Loading dose: 70 mg on day 1, then 50 mg daily (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis, oropharyngeal (refractory disease) (alternative therapy): </b>IV: Initial dose: 70 mg on day 1; subsequent doses: 50 mg once daily (IDSA [Pappas 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Fungal infections, empiric therapy in neutropenic patients:</b> IV: Initial dose: 70 mg on day 1; followed by 50 mg once daily. Continue until resolution of neutropenia; if fungal infection confirmed, continue for a minimum of 14 days (at least 7 days after resolution of both neutropenia and clinical symptoms). If clinical response inadequate, may increase up to 70 mg once daily if tolerated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for concomitant administration:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients receiving rifampin:</i> Infants &ge;3 months, Children, and Adolescents: IV: 70 mg/m<sup>2</sup>/dose caspofungin once daily; maximum dose: 70 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients receiving carbamazepine, dexamethasone, phenytoin, nevirapine, or efavirenz (and possibly other enzyme inducers</i>): Infants &ge;3 months, Children, and Adolescents: IV: May require an increase in caspofungin dose to 70 mg/m<sup>2</sup>/dose once daily; maximum dose: 70 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants &ge;3 months, Children, Adolescents, and Adults: No adjustment needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">End-stage renal disease (ESRD) requiring dialysis: Poorly dialyzed; no supplemental dose or dosage adjustment necessary in patients on intermittent hemodialysis (IHD). No supplemental dose or dosage adjustment needed in peritoneal dialysis or continuous renal replacement therapy (eg, CVVHD) (Aronoff 2007; Heintz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); based on experience in adult patients, dosage reduction may be necessary; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild hepatic impairment (Child-Pugh class A): No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate hepatic impairment (Child-Pugh class B): 70 mg on day 1 (where recommended), followed by 35 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe hepatic impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146769\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea); 70 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as acetate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cancidas: 50 mg (1 ea); 70 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea); 70 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146756\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045817\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer by slow IV infusion over 1 hour (manufacturer); higher doses (eg, 150 mg) have been infused over ~2 hours (Betts 2009). Monitor during infusion; isolated cases of possible histamine-related reactions have occurred during clinical trials (rash, flushing, pruritus, facial edema).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146783\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Reconstituted solution may be stored at &le;25&deg;C (&le;77&deg;F) for up to 1 hour prior to preparation of infusion solution. Solutions diluted in NS, <sup>1</sup>/<sub>2</sub>NS, <sup>1</sup>/<sub>4</sub>NS, or LR for infusion should be used within 24 hours when stored at &le;25&deg;C (&le;77&deg;F) or within 48 hours when stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045816\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies; treatment of candidemia, intra-abdominal abscess, peritonitis, and pleural space infection caused by susceptible <i>Candida</i> species; treatment of esophageal candidiasis; empiric therapy of presumed fungal infection in febrile neutropenic patients (All indications: FDA approved in ages &ge;3 months and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146817\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Atrial fibrillation, bradycardia, cardiac arrhythmia, edema, flushing, hypertension, hypotension (more common in adults), myocardial infarction, peripheral edema (adults), tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, chills (more common in adults), confusion, depression, dizziness, drowsiness, fatigue, headache, insomnia, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Decubitus ulcer (adults), erythema, pruritus (infants, children, and adolescents), skin lesion, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypercalcemia, hyperglycemia (adults), hypervolemia, hypokalemia, hypomagnesemia (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distention, abdominal pain, anorexia, constipation, decreased appetite, diarrhea (more common in adults), dyspepsia, mucosal inflammation, nausea (more common in adults), upper abdominal pain, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Nephrotoxicity (adults; serum creatinine &ge;2 x baseline value or &ge;1 mg/dL in patients with serum creatinine above ULN range), urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (adults), blood coagulation disorder, decreased hematocrit (adults), decreased hemoglobin (adults), decreased white blood cell count (adults), febrile neutropenia, neutropenia, petechia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Decreased serum albumin (adults), hepatic failure, hepatomegaly, hepatotoxicity, hyperbilirubinemia, increased serum alkaline phosphatase (adults), increased serum ALT (more common in adults), increased serum AST (more common in adults), increased serum bilirubin (adults), jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Bacteremia, sepsis (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Catheter infection (infants, children, and adolescents), infusion site reaction (pain/pruritus/swelling), localized phlebitis (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, limb pain, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Hematuria (adults), increased blood urea nitrogen (adults), increased serum creatinine (adults), renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough (adults), dyspnea (adults), epistaxis, hypoxia, pleural effusion (adults), pneumonia (adults), rales (adults), respiratory distress (adults), respiratory failure (adults), tachypnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, infusion related reaction, septic shock (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, erythema multiforme, hepatitis, histamine release (including facial swelling, bronchospasm, sensation of warmth), increased gamma-glutamyl transferase, pancreatitis, Stevens-Johnson syndrome, swelling, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146775\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to caspofungin or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for echinocandin antifungals is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146760\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Increased transaminases and rare cases of clinically significant hepatic dysfunction (including failure and hepatitis) have been reported in pediatric and adult patients. Monitor liver function tests during therapy; if tests become abnormal or worsen, consider discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Anaphylaxis, other hypersensitivity reactions, histamine-related reactions (eg, angioedema, facial swelling, bronchospasm, rash, sensation of warmth), and cases of Stevens-Johnson syndrome and toxic epidermal necrolysis (some fatal) have been reported. Discontinue if a hypersensitivity reaction occurs. Administer supportive treatment if needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage reduction required in adults with moderate hepatic impairment (Child-Pugh class B); safety and efficacy have not been established in children with any degree of hepatic impairment and adults with severe hepatic impairment (Child-Pugh class C).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298979\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146764\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12914&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the adverse/toxic effect of Caspofungin. CycloSPORINE (Systemic) may increase the serum concentration of Caspofungin. Management: Weigh potential benefits of caspofungin against a possible elevated risk of hepatotoxicity.  Monitor liver function and re-evaluate treatment in patients with abnormal values.  Mild transaminase elevations may occur relatively commonly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inducers of Drug Clearance: May decrease the serum concentration of Caspofungin. Management: Consider using an increased caspofungin dose of 70 mg daily in adults (or 70 mg/m<sup>2</sup>, up to a maximum of 70 mg, daily in pediatric patients) when coadministered with known inducers of drug clearance.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Caspofungin. Management: Caspofungin prescribing information recommends using a dose of 70 mg daily in adults (or 70 mg/m<sup>2</sup>, up to a maximum of 70 mg, daily in pediatric patients) who are also receiving rifampin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Caspofungin may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146766\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146777\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. When treatment of invasive <i>Aspergillus</i> or <i>Candida</i> infections is needed during pregnancy, other agents are preferred (HHS [adult] 2017; IDSA [Pappas 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045812\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic liver function tests, serum potassium, CBC, hemoglobin; signs of anaphylaxis or histamine-related reactions</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146759\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits synthesis of &beta;(1,3)-D-glucan, an essential component of the cell wall of susceptible fungi. Highest activity is in regions of active cell growth. Mammalian cells do not require &beta;(1,3)-D-glucan, limiting potential toxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146774\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: CSF concentrations: Nondetectable [&lt;10 ng/mL (n=1)] (S&aacute;ez-Llorens 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~97% to albumin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Slowly, via hydrolysis and <i>N</i>-acetylation as well as by spontaneous degradation, with subsequent metabolism to component amino acids. Overall metabolism is extensive. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Beta (distribution): 9 to 11 hours (~8 hours in children &lt;12 years); Terminal: 40 to 50 hours; beta phase half-life is 32% to 43% lower in pediatric patients than in adult patients </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (41%; primarily as metabolites, ~1% of total dose as unchanged drug); feces (35%; primarily as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323044\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Cancidas Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $405.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70 mg (1): $421.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Caspofungin Acetate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $269.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70 mg (1): $122.22</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146778\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>BDCASPO (PH);</li>\n      <li>Cancidas (AE, AR, AT, AU, BB, BE, BG, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IN, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UY, VE, VN);</li>\n      <li>Kansydaz (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007; p 98, 170.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Betts RF, Nucci M, Talwar D, et al, &quot;A Multicenter, Double-Blind Trial of a High-Dose Caspofungin Treatment Regimen Versus a Standard Caspofungin Treatment Regimen for Adult Patients With Invasive Candidiasis,&quot; <i>Clin Infect Dis</i>, 2009, 48(12):1676-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-pediatric-drug-information/abstract-text/19419331/pubmed\" target=\"_blank\" id=\"19419331\">19419331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Nelson JD, Barnett E, et al. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 23rd ed. American Academy of Pediatrics; 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cancidas for injection (caspofungin) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc; February 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-pediatric-drug-information/abstract-text/19419331/pubmed\" target=\"_blank\" id=\"19419331\">19419331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Department of Health and Human Services. December 2016. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-pediatric-drug-information/abstract-text/19419331/pubmed\" target=\"_blank\" id=\"19419331\">19419331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. November 2016. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-pediatric-drug-information/abstract-text/19419331/pubmed\" target=\"_blank\" id=\"19419331\">19419331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeon GW, Sin JB. Successful caspofungin treatment of persistent candidemia in extreme prematurity at 23 and 24 weeks' gestation. <i>J Formos Med Assoc</i>. 2014;113(3):191-194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-pediatric-drug-information/abstract-text/24534016/pubmed\" target=\"_blank\" id=\"24534016\">24534016</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. <i>J Clin Oncol</i>. 2017;35(18):2082-2094.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-pediatric-drug-information/abstract-text/28459614/pubmed\" target=\"_blank\" id=\"28459614\">28459614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mohamed WA, Ismail M. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants. <i>J Trop Pediatr</i>. 2012;58(1):25-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-pediatric-drug-information/abstract-text/21355042/pubmed\" target=\"_blank\" id=\"21355042\">21355042</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-pediatric-drug-information/abstract-text/26679628/pubmed\" target=\"_blank\" id=\"26679628\">26679628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;63(4):e1-e60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-pediatric-drug-information/abstract-text/27365388/pubmed\" target=\"_blank\" id=\"27365388\">27365388</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    S&aacute;ez-Llorens X, Macias M, Maiya P, et al, &quot;Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less Than 3 Months of Age,&quot; <i>Antimicrob Agents Chemother</i>, 2009, 53(3):869-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-pediatric-drug-information/abstract-text/19075070/pubmed\" target=\"_blank\" id=\"19075070\">19075070</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walsh TJ, Adamson PC, Seibel NL, et al, &quot;Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents,&quot; <i>Antimicrob Agents Chemother</i>, 2005, 49(11):4536-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/caspofungin-pediatric-drug-information/abstract-text/16251293/pubmed\" target=\"_blank\" id=\"16251293\">16251293</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12914 Version 110.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F146788\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F146789\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045813\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442199\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045806\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F146769\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F146756\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045817\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F146783\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045816\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F146817\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F146775\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F146760\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298979\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F146764\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F146766\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F146777\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045812\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F146759\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F146774\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323044\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F146778\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12914|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=caspofungin-drug-information\" class=\"drug drug_general\">Caspofungin: Drug information</a></li><li><a href=\"topic.htm?path=caspofungin-patient-drug-information\" class=\"drug drug_patient\">Caspofungin: Patient drug information</a></li></ul></div></div>","javascript":null}